文献速递慢性肾脏病血液净化与透析

重新审视CKD试验的肾脏结局:eGFR斜率、竞争风险与实用性试验设计

Reframing kidney outcomes in CKD trials: eGFR slopes, competing risks, and pragmatic trial design.
PubMed 文献 · Nephrol Dial Transplant · 2026-08-17

本综述讨论慢性肾脏病(CKD)临床试验结局定义的转变,包括eGFR斜率作为替代终点、竞争风险方法在高死亡率CKD和透析人群中的必要性,以及基于注册的实用性试验。文章提出eGFR斜率可直观展示「肾脏时间」,并将竞争风险视为临床问题,建议实用性CKD试验整合斜率终点和竞争风险分析。

要点

  • eGFR斜率可作为CKD试验的替代终点,但需在适当条件下解读。
  • 竞争风险在高死亡率CKD和透析人群中影响标准生存分析的准确性。
  • 实用性注册试验可纳入更接近日常实践的患者,应整合斜率与竞争风险分析。

核心结论

  • eGFR斜率、至肾衰竭时间和竞争风险因素应整体考虑,以帮助患者和临床医生理解CKD和心血管证据。
  • eGFR斜率可能提供「肾脏时间」的临床直观总结,在适当条件下慢性斜率差异可在人群水平转化为大约「透析延迟年数」。
  • 竞争风险应被视为临床问题而非仅统计学问题,实用性CKD试验应整合斜率终点和竞争风险分析。

研究设计与样本

  • 综述,未报告系统检索范围与样本量。

主要发现

  • 新分子可测试及肾脏病宜早期治疗,使需「硬终点」的研究时长对注册和资助机构不可行。
  • 数学建模与统计分析改进、电子病历和注册登记可用性影响了肾脏病临床研究。
  • eGFR斜率被 promoted 为肾衰竭的替代终点,竞争风险方法暴露了标准生存分析在高死亡率CKD和透析人群中的局限性。
  • 实用性、基于注册的试验纳入与日常实践相似的患者。

临床怎么用

  • 在CKD试验设计与报告中整合eGFR斜率终点和竞争风险分析。
  • 临床解读CKD和心血管证据时,应综合考虑eGFR斜率、至肾衰竭时间和竞争风险因素。
  • 采用实用性注册试验设计,纳入更接近日常实践的患者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

In both clinical research and study design, the definition of outcomes for chronic kidney disease (CKD) is changing. New molecules available for testing in humans, and the fact that kidney diseases are best treated earlier in their course, make the duration of studies requiring 'hard endpoints' longer than is feasible for registration purposes and funding agencies. Improved mathematical modelling and statistical analyses, and the availability of electronic medical records and registries have also impacted nephrology clinical research. Thus, eGFR slopes have been promoted as surrogate endpoints for kidney failure, competing-risk methods have exposed the limitations of standard survival analysis in high-mortality CKD and dialysis populations, and pragmatic, registry-based trials enroll patients who resemble those seen in daily practice. This review suggests that eGFR slopes, time to kidney failure, and competing risk factors must be considered in their totality, so that CKD and cardiovascular (CV) evidence can be understood in clinical practice by patients and clinicians. We propose that eGFR slopes may provide a clinically intuitive summary of 'kidney time', showing how, under appropriate conditions, chronic slope differences may be translated into approximate 'years of dialysis delayed' at the population level. We frame competing risks as a clinical, not only statistical, issue, and we examine how pragmatic CKD trials can and should integrate slope-based endpoints and competing-risk analyses into their design and reporting. To advance nephrology research, we must embrace these changes in study design and methodology to ensure that clinicians and patients understand them, and thus are more prepared to implement trial results.

来源:Nephrol Dial Transplant,查看原文。版权归原作者所有。

引用

  1. Zoccali C, Levin A. Reframing kidney outcomes in CKD trials: eGFR slopes, competing risks, and pragmatic trial design. Nephrol Dial Transplant. 2026. PMID: 42606392. doi:10.1093/ndt/gfag176

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。